JP7720829B2 - Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 - Google Patents

Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Info

Publication number
JP7720829B2
JP7720829B2 JP2022505198A JP2022505198A JP7720829B2 JP 7720829 B2 JP7720829 B2 JP 7720829B2 JP 2022505198 A JP2022505198 A JP 2022505198A JP 2022505198 A JP2022505198 A JP 2022505198A JP 7720829 B2 JP7720829 B2 JP 7720829B2
Authority
JP
Japan
Prior art keywords
phenyl
difluoromethoxy
ethyl
trifluoromethoxy
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022505198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543203A5 (enExample
JP2022543203A (ja
Inventor
サムズ，アネット，グラベン
ロットランダー，マリオ
ラーセン，クレステン
ワン，シャオファン
ダス，デバシス
ホン，ジアン
チェン，シュ，フイ
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2022543203A publication Critical patent/JP2022543203A/ja
Publication of JP2022543203A5 publication Critical patent/JP2022543203A5/ja
Priority to JP2025112976A priority Critical patent/JP7897992B2/ja
Application granted granted Critical
Publication of JP7720829B2 publication Critical patent/JP7720829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2022505198A 2019-08-02 2020-07-30 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 Active JP7720829B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112976A JP7897992B2 (ja) 2019-08-02 2025-07-03 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19189750.3 2019-08-02
EP19189750 2019-08-02
CN201910734123.0 2019-08-09
CN201910734123 2019-08-09
EP19191887 2019-08-15
EP19191887.9 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112976A Division JP7897992B2 (ja) 2019-08-02 2025-07-03 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Publications (3)

Publication Number Publication Date
JP2022543203A JP2022543203A (ja) 2022-10-11
JP2022543203A5 JP2022543203A5 (enExample) 2023-08-04
JP7720829B2 true JP7720829B2 (ja) 2025-08-08

Family

ID=71894829

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022505198A Active JP7720829B2 (ja) 2019-08-02 2020-07-30 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
JP2025112976A Active JP7897992B2 (ja) 2019-08-02 2025-07-03 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112976A Active JP7897992B2 (ja) 2019-08-02 2025-07-03 Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Country Status (27)

Country Link
EP (2) EP4461725A3 (enExample)
JP (2) JP7720829B2 (enExample)
KR (1) KR102957984B1 (enExample)
CN (1) CN114206830B (enExample)
AU (1) AU2020325517B2 (enExample)
BR (1) BR112021006324A2 (enExample)
CA (1) CA3148719A1 (enExample)
CL (1) CL2022000221A1 (enExample)
CO (1) CO2022000080A2 (enExample)
CR (1) CR20220028A (enExample)
DO (1) DOP2022000026A (enExample)
EC (1) ECSP22008993A (enExample)
ES (1) ES2989376T3 (enExample)
GE (2) GEAP202415862A (enExample)
HR (1) HRP20241444T1 (enExample)
HU (1) HUE069310T2 (enExample)
IL (1) IL290193B2 (enExample)
JO (1) JOP20220017A1 (enExample)
MA (1) MA56708B1 (enExample)
MX (1) MX2022001063A (enExample)
PE (1) PE20220345A1 (enExample)
PH (1) PH12022550192A1 (enExample)
PL (1) PL4007634T3 (enExample)
RS (1) RS66130B1 (enExample)
SM (1) SMT202400445T1 (enExample)
WO (1) WO2021023617A1 (enExample)
ZA (1) ZA202109598B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160211A (ja) * 2019-08-02 2025-10-22 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024310446A1 (en) * 2023-06-27 2026-01-22 Saniona A/S Kv7 modulators
WO2026132415A1 (en) * 2024-12-20 2026-06-25 Saniona A/S Kv7 modulators

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513451A (ja) 2004-09-15 2008-05-01 ブリストル−マイヤーズ スクイブ カンパニー ４−アリールスピロシクロアルキル−２−アミノピリミジンカルボキサミドｋｃｎｑカリウムチャネル調節剤
JP2009530237A (ja) 2006-03-15 2009-08-27 ノイロサーチ アクティーゼルスカブ キナゾリノン及びカリウムチャネル活性化剤としてのその使用
WO2010060955A1 (en) 2008-11-27 2010-06-03 Neurosearch A/S Novel 2-morpholino-3-amido-pyridine derivatives and their medical use
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
JP2016504306A (ja) 2012-12-10 2016-02-12 ハー・ルンドベック・アクチエゼルスカベット ニコチン性アセチルコリン受容体の新規な陽性アロステリックモジュレータ
WO2016040952A2 (en) 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
CN105663136A (zh) 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用
JP7121144B2 (ja) 2018-02-20 2022-08-17 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
JP2022543230A (ja) 2019-08-02 2022-10-11 ハー・ルンドベック・アクチエゼルスカベット てんかん又はてんかん発作において使用するためのＫｖ７カリウムチャネル開口薬としてのアルコール誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893858B2 (en) 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090118285A1 (en) 2006-02-07 2009-05-07 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
CN101790374A (zh) 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
US10590067B2 (en) * 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
ES2989376T3 (es) * 2019-08-02 2024-11-26 H Lundbeck As Derivados de alcohol como abridores del canal de potasio Kv7

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513451A (ja) 2004-09-15 2008-05-01 ブリストル−マイヤーズ スクイブ カンパニー ４−アリールスピロシクロアルキル−２−アミノピリミジンカルボキサミドｋｃｎｑカリウムチャネル調節剤
JP2009530237A (ja) 2006-03-15 2009-08-27 ノイロサーチ アクティーゼルスカブ キナゾリノン及びカリウムチャネル活性化剤としてのその使用
WO2010060955A1 (en) 2008-11-27 2010-06-03 Neurosearch A/S Novel 2-morpholino-3-amido-pyridine derivatives and their medical use
JP2016504306A (ja) 2012-12-10 2016-02-12 ハー・ルンドベック・アクチエゼルスカベット ニコチン性アセチルコリン受容体の新規な陽性アロステリックモジュレータ
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2016040952A2 (en) 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
CN105663136A (zh) 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用
JP7121144B2 (ja) 2018-02-20 2022-08-17 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
JP2022543230A (ja) 2019-08-02 2022-10-11 ハー・ルンドベック・アクチエゼルスカベット てんかん又はてんかん発作において使用するためのＫｖ７カリウムチャネル開口薬としてのアルコール誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160211A (ja) * 2019-08-02 2025-10-22 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
JP7897992B2 (ja) 2019-08-02 2026-07-30 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Also Published As

Publication number Publication date
RS66130B1 (sr) 2024-11-29
EP4007634C0 (en) 2024-10-02
MX2022001063A (es) 2022-02-14
ES2989376T3 (es) 2024-11-26
HUE069310T2 (hu) 2025-02-28
CN114206830B (zh) 2024-07-30
EP4461725A3 (en) 2025-01-15
CL2022000221A1 (es) 2022-10-07
KR20220041084A (ko) 2022-03-31
JP7897992B2 (ja) 2026-07-30
JOP20220017A1 (ar) 2023-01-30
GEP20247629B (en) 2024-06-10
BR112021006324A2 (pt) 2022-02-15
CO2022000080A2 (es) 2022-01-17
DOP2022000026A (es) 2022-03-31
PH12022550192A1 (en) 2022-11-21
CR20220028A (es) 2022-03-02
MA56708B1 (fr) 2024-12-31
IL290193B1 (en) 2024-08-01
CN114206830A (zh) 2022-03-18
ECSP22008993A (es) 2022-03-31
ZA202109598B (en) 2024-04-24
AU2020325517A1 (en) 2022-02-24
KR102957984B1 (ko) 2026-04-27
EP4461725A2 (en) 2024-11-13
GEAP202415862A (en) 2024-01-25
IL290193A (en) 2022-03-01
SMT202400445T1 (it) 2024-11-15
JP2022543203A (ja) 2022-10-11
PL4007634T3 (pl) 2024-11-25
AU2020325517B2 (en) 2025-08-28
IL290193B2 (en) 2024-12-01
WO2021023617A1 (en) 2021-02-11
JP2025160211A (ja) 2025-10-22
PE20220345A1 (es) 2022-03-14
CA3148719A1 (en) 2021-02-11
EP4007634B1 (en) 2024-10-02
EP4007634A1 (en) 2022-06-08
HRP20241444T1 (hr) 2024-12-20

Similar Documents

Publication Publication Date Title
JP7121144B2 (ja) Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
JP2025160211A (ja) Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
US20240327336A1 (en) Alcohol derivatives as kv7 potassium channel openers
US12258305B2 (en) Alcohol derivatives as Kv7 potassium channel openers
JP7591036B2 (ja) てんかん又はてんかん発作において使用するためのＫｖ７カリウムチャネル開口薬としてのアルコール誘導体
RU2822797C2 (ru) СПИРТОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ СОЕДИНЕНИЙ, ИНДУЦИРУЮЩИХ ОТКРЫТИЕ КАЛИЕВЫХ КАНАЛОВ Kv7
EA048113B1 (ru) СПИРТОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ СОЕДИНЕНИЙ, ИНДУЦИРУЮЩИХ ОТКРЫТИЕ КАЛИЕВЫХ КАНАЛОВ Kv7
HK40111501A (en) Alcohol derivatives as kv7 potassium channel openers
BR112019021960B1 (pt) Composto que ativa os canais de potássio kv7, seu uso e composição farmacêutica compreendendo o mesmo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7720829

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150